# Abemaciclib with pembrolizumab in breast or lung cancer

Source: https://onco.cc/trials/nct02779751/  
OnCo record `nct02779751` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This early study tests abemaciclib with pembrolizumab in selected advanced breast and lung cancers. It examines safety and treatment activity.

## Summary

This early study tests abemaciclib with pembrolizumab in selected advanced breast and lung cancers. It examines safety and treatment activity.

Interventional study registered as NCT02779751, sponsored by Eli Lilly and Company. Registry phase: 1. Registry enrollment is 100 participants (estimated). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-10
- Also known as: A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT02779751
- Phase: 1
- Setting: Advanced hormone receptor-positive, HER2-negative breast cancer or non-small cell lung cancer
- Sponsor: Eli Lilly and Company

## Sources

- ClinicalTrials.gov NCT02779751: https://clinicaltrials.gov/study/NCT02779751
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT02779751

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Anastrozole](https://onco.cc/drugs/anastrozole/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct02779751.json